We conducted a genome-wide association study (GWAS) and a follow-up study of bipolar disorder (BD), a common neuropsychiatric disorder. In the GWAS, we investigated 499,494 autosomal and 12,484 X-chromosomal SNPs in 682 patients with BD and in 1300 controls. In the first follow-up step, we tested the most significant 48 SNPs in 1729 patients with BD and in 2313 controls. Eight SNPs showed nominally significant association with BD and were introduced to a meta-analysis of the GWAS and the first follow-up samples. Genetic variation in the neurocan gene (NCAN) showed genome-wide significant association with BD in 2411 patients and 3613 controls (rs1064395, p ¼ 3.02 3 10
Bipolar disorder (BD [MIM 125480]) is a highly heritable disorder of mood, characterized by recurrent episodes of mania and depression that are often accompanied by behavioral and cognitive disturbances. Linkage and candidate-gene studies were the only available approaches for unraveling the genetic underpinnings of the disorder until the recent introduction of genome-wide association studies (GWAS). To date, six GWAS using common SNPs have been published. [1] [2] [3] [4] [5] [6] Although there has been only limited consistency across studies regarding the top associated genomic regions, [1] [2] [3] 5, 6 meta-analyses of some of these studies have revealed common association signals: a metaanalysis 7 of the Baum et al. 2 and Wellcome Trust Case
Control Consortium (WTCCC) 1 data sets found evidence of a consistent association between BD and variants in the genes JAM3 (MIM 606871) (rs10791345, p ¼ 1 3 10 À6 ) and SLC39A3 (MIM 612168) (rs4806874, p ¼ 5 3 10 À6 ). A combined analysis 4 of the Sklar et al. 3 and WTCCC 1 studies, which included a total of 4387 patients and 6209 controls, identified a genome-wide significant association signal for BD in ANK3 (MIM 600465) (rs10994336, p ¼ 9.1 3 10 À9 ). The second strongest finding was for rs1006737 in CACNA1C (MIM 114205) (p ¼ 7 3 10 À8 ). Further independent support for ANK3 rs10994336 has recently been found by Schulze et al. 8 in samples from Germany (overlapping with samples used in the present GWAS; see Table S1 available online) and the USA; the same study 8 reported evidence for allelic heterogeneity at the ANK3 locus. Although GWAS studies of BD have identified a number of potentially relevant genetic variants, the widely acknowledged formal threshold for genome-wide significance of p ¼ 5 3 10
À8
has been surpassed only for variation in ANK3 so far.
In the present study, we performed a GWAS and a twostep follow-up study of clinically well-characterized BD samples from Europe, the USA, and Australia. The GWAS and replication I included only European BD samples and produced genome-wide significant evidence for association in the neurocan gene (NCAN [MIM 600826 In the following text, we provide a phenotype description of the samples used in each step of our study (GWAS, replication I, replication II), specifications of the SNP genotyping, and the quality control (QC) measures applied to the raw genotyping data:
The patients included in our GWAS and replication I step received a lifetime diagnosis of BD according to the DSM-IV 9 criteria on the basis of a consensus best-estimate procedure 10 and structured diagnostic interviews. 11, 12 Protocols and procedures were approved by the local ethics committees. Written informed consent was obtained from all patients and controls. They were recruited from consecutive admissions to psychiatric inpatient units at ( Figure S2 ). At the marker Patients received diagnoses according to the indicated diagnostic criteria and interviews. Protocols and procedures were approved by the local Ethics Committees. Written informed consent was obtained from all patients and controls. Ancestry was assigned to patients and controls on the basis of self-reported ancestry. The samples from Bosnia and Herzegovina / Serbia were merged due to the small number of subjects. level, nonrandom missingness patterns were identified with the use of PLINK's ''mishap'' test, and another 1825 SNPs were excluded. In total, we excluded 20 patients and 68 controls as well as 49,488 SNPs in the course of our QC before association analysis. The effect of our QC on the resulting p values with data sets has been depicted in a quantile-quantile plot ( Figure S1 ). The genomic inflation factor (l) after QC was 1.071 (1.107 before QC).
The follow-up SNP set (replication I) was genotyped on the MALDI TOF-based MassARRAY system with the use of the iPLEX Gold assay (Sequenom, San Diego, CA, USA). The iPLEX primer sequences and assay conditions may be obtained from the authors upon request. Of the top 79 SNPs from the GWAS, 18 were excluded from the follow-up step on the basis of linkage disequilibrium (LD), failed assay design, or poor genotype clustering in the iPLEX genotyping assay. Of the remaining 61 SNPs, 13 did not pass our QC filters (six SNPs with CR < 0.95, two SNPs with nonrandom differences in missingness patterns between subsamples, one SNP with an MAF < 0.01 in controls, and four SNPs with deviations from HWE [p exact < 1 3 10 À4 in controls]). In total, 181 individuals were excluded (n ¼ 31 cryptically related individuals, n ¼ 150 with call rates < 95%). To identify the cryptically related individuals (IBS > 1.65), we had computed an IBS matrix on the basis of the quality-controlled GWAS sample and all six replication samples. For the replication II step, NCAN rs1064395 genotypes were extracted from the following genome-wide data sets: GAIN-EA 6 /TGEN1, WTCCC-BD, 1 Germany III, France, Iceland, Australia, and Norway, which are described in Table 1 and Table S2 .
The quality-controlled genotype data were subjected to the following association tests: In the GWAS and replication I steps, analyses were computed with PLINK 17 (version 1.05). Autosomal-wide analysis was performed via the TREND test with 1 degree of freedom (df). The X chromosome (females and males combined) was analyzed via the Wald test with 1 df. In replication I and the meta-analysis (GWAS and replication I), autosomal and X-chromosomal SNPs were investigated via the Cochran-Mantel-Haenszel (CMH) test, stratified for ethnicity with the use of a 2 3 2 3 K table in which K ¼ 6, reflecting the six European countries. The CMH test was two-tailed for all analyses.
To investigate the homogeneity of ORs for the replicated SNPs, we used the Breslow-Day test. We selected p < 5 3 10 À8 as the threshold for genome-wide significance, assuming one million noncorrelated common SNPs in the genome, as proposed by the Diabetes Genetics Initiative 18 and the International HapMap Consortium. 19 In the replication II step, NCAN rs1064395 was investigated via logistic regression (assuming an additive effect), which was a two-tailed test. NCAN rs1064395 was also investigated with the use of a fixed-effects meta-analysis based on the weighted Z-score method, 20 which was two-tailed for replication II samples (n ¼ 7) and for the combined analysis of all study samples (n ¼ 14).
On the basis of the QC specifications and statistical procedures described above, we performed a GWAS of 682 BD patients and 1300 controls (Table 1) , using 499,494 autosomal SNPs and 12,484 X-chromosomal SNPs. A genome-wide overview of the GWAS p values is given in Figure 1A . In the first follow-up step (replication I), we genotyped the most significant 48 SNPs (autosomal SNPs: p % 7.57 3 10 À5 ; X-chromosomal SNPs: p % 1.89 3 10 À4 ; for SNPs in LD (r 2 R 0.8), only the SNP with the smallest GWAS p value was genotyped in the follow-up) in six European follow-up samples comprising a total of 1729 BD patients and 2313 controls ( Table 1 ).
The same set of instruments was used across all centers. 21 In the replication, we used phenotypically more relaxed criteria than in the initial GWAS and also included patients with a diagnosis of BD type II, schizoaffective disorder (bipolar type), and BD not otherwise specified. To account for possible heterogeneity, autosomal and X-chromosomal we investigated SNPs via the CMH test and stratified them with regard to ethnicity. Eight of the 48 SNPs showed nominally significant association in the combined replication samples, all with the same alleles as in the GWAS ( Table 2, Table S3 ). This number of replicated SNPs is significantly higher than would be expected to occur by chance (n expected ¼ 2. Figure S3 ) was not replicated (p ¼ 0.5772). Given that our follow-up samples were derived from six different European countries, we specifically tested for possible heterogeneity by using the replication data. In the case of the successfully replicated SNPs, there was no evidence of ethnic heterogeneity (Breslow-Day p min ¼ 0.178). In support of this was the observation that subtraction of any individual replication sample did not markedly alter the effect sizes (Table S4) .
In a subsequent analysis, we applied a meta-analysis approach (CMH test) to combine all investigated samples. SNP rs1064395 in NCAN surpassed the threshold for genome-wide significance (p ¼ 3.02 3 10 À8 , OR ¼ 1.31; Figure 1B) The most associated marker from the GWAS (enlarged red diamond) is centered in a genomic window of 1 Mb (hg18, RefSeq genes); its p value from the combined analysis (meta) is shown (enlarged blue diamond). The LD strength (r 2 ) between the sentinel SNP from the GWAS and its flanking markers is demonstrated by the red (high) to white (low) color bar. The recombination rate (cM/Mb; second y axis) is plotted in blue, according to HapMap-CEU. RAPs were generated with SNAP. 42 In all seven patient samples, the A allele was overrepresented ( The combined analysis of all study samples (GWAS þ replication I þ replication II), with 8441 patients and 35,362 controls, resulted in p ¼ 2.14 3 10 À9 (OR ¼ 1.17). An overview of the significance levels and genetic effect sizes of NCAN rs1064395 at all steps of analysis is provided in Figure 2 and Table 3 . It is interesting to note that there is no improvement of the OR when we perform an analysis of BD type I only (OR ¼ 1.16), providing no strong evidence that genetic variation in NCAN would have a much stronger effect in BD type I compared to the other diagnoses included in our study (BD type II, schizoaffective disorder [bipolar type], and BD not otherwise specified).
Neurocan was originally described in the rat brain, 22 where its expression decreases significantly in the first week after birth. 23 To validate whether Ncan is expressed in brain areas previously implicated in BD, 24 we performed RNA in situ hybridization with whole mounts and sections from embryonic and postnatal wild-type mice, using procedures described previously. 25 We amplified Ncan probes from postnatal day 46 (P46) mouse brain cDNA (strain C57BL/6), covering nucleotides 5715-6515 of GenBank accession NM_007789.3. This was cloned into pCRII-TOPO vector (Invitrogen, Karlsruhe, Germany). Animals 
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The following abbreviations are used: TREND, Cochran-Armitage test; CMH, Cochran-Mantel-Haenszel test; FEM, fixed-effects meta-analysis based on the weighted z-score method; 20 L, logistic regression assuming an additive effect; OR, odds ratio referring to the minor allele (MA); n, number of analyzed study samples; MAF, MA frequency; Pat, patients; Con, controls.
were handled according to European and German laws. At embryonic day 14.5 (E14.5), Ncan expression was confined to the central nervous system ( Figure 3A) . However, Ncan transcripts have also been described in the peripheral nervous system in later developmental stages. 26 Between E14.5 and E16.5, Ncan was highly expressed in the cortical plate, as well as in the ventricular zone of the basal ganglia ( Figures 3A-3C ). In the subventricular zone of the neocortex, the transcripts were located mainly in the caudal region ( Figure 3C ), where neurocan proteins may be involved in axon guidance. 27 Ncan was also present in the developing hippocampus (data not shown). After birth, its general expression was found to be decreased. It was detected in the dentate gyrus and CA1 of the hippocampus ( Figure 3E ), as well as in the cortical layer II ( Figure 3D ) at P46. Its expression in the cortical layer II remained unabated, at least up to P18, with higher expression in the frontal cortex (data not shown). On the contrary, Ncan expression was not detected in any hippocampal area at this age. To investigate whether NCAN and MAD1L1 are expressed in the human brain, we analyzed the transcriptional expression of both genes in human hippocampus tissue samples (n ¼ 148), using data from whole-genome HumanHT-12 Expression BeadChips (Illumina, San Diego, USA). Tissues were obtained from surgery on patients with pharmaco-resistant epilepsy. Total RNA was isolated from fresh frozen tissues and underwent QC via BioAnalyzer measurements (Agilent Technologies, Waldbronn, Germany). The background of expression profiles was subtracted and signals were normalized (average-normalization) with Illumina's GenomeStudio software. The analysis showed that NCAN and MAD1L1 were expressed in the hippocampus ( Figure S6 ). For NCAN, an average signal-intensity log 2 ratio of 7.99 with a standard deviation of 0.8 (intensities, min ¼ 5.82 and max ¼ 10.4) was detected, and for MAD1L1, an average signal-intensity log 2 ratio of 5.21 with a standard deviation of 0.46 (intensities, min ¼ 3.55 and max ¼ 6.1) was detected.
Our GWAS and follow-up study of BD samples, including a total of 43,803 individuals (8441 patients and 35,362 controls), provided a significant level of statistical support for the idea that common genetic variation in NCAN is involved in the etiology of this common and severe neuropsychiatric disorder. The overall p value for the top-associated SNP, rs1064395, was 2.14 3 10
À9
(OR ¼ 1.17). NCAN encodes neurocan (MIM 600826), an extracellular matrix glycoprotein. The gene is highly expressed in the brain, and is thought to be involved in cell adhesion and migration. To map its spatiotemporal expression, we performed in situ hybridizations in embryonic and postnatal wild-type mice. We observed that murine Ncan was expressed in cortical and hippocampal areas and could confirm that NCAN transcripts are highly abundant in the human hippocampus. These brain regions, E) . In the embryo, Ncan is observed exclusively in the CNS, with high expression in the cortical plate (Cp) and subventricular zone (Sz, arrow in C) of the neocortex and in the ventricular zone of the basal ganglia (Bg, A-C). Ncan was also detected in the hypothalamus (Ht) and amygdala (Am, B). In postnatal mice, Ncan expression in the cortex (Cx) is restricted to layer II (arrow in D). In the hippocampus (E), it was detected at lower intensity in the dentate gyrus (Dg) and CA1. Lv indicates the lateral ventricle.
which are involved in cognition and regulation of circuits involved in emotion, have previously been implicated in BD by neuropsychological, neuroimaging, and postmortem studies. 28 Ncan-deficient mice show no obvious defect in brain morphology, and basic synaptic transmission appears to be normal. 26 However, the maintenance of late-phase long-term potentiation in the hippocampal CA1 region in null mutants is reduced, which could lead to mild deficits in learning and memory; 26 i.e., there are disturbances in the mechanisms that underlie the cognitive deficits observed in BD. This suggests that Ncan-deficient mice should be reexamined for more subtle changes in the brain, such as synaptic plasticity. MAD1L1 (mitotic arrest deficient-like 1 [MIM 602686]) is a component of the chromosome spindle-assembly checkpoint in mitosis. Defects in mitotic checkpoints can lead to aneuploidy, which may play a role in carcinogenesis and aging. 29 Homozygous knockout of Mad1l1 in mice confers embryonic lethality, which indicates that it has an essential function in development. 30 MAD1L1 is expressed in the human hippocampus ( Figure S6 ), although its neurobiological effects have not been established. In summary, the present study has identified a susceptibility factor for BD, NCAN, and a potential BD susceptibility factor, MAD1L1. Expression studies in mice provide strong support for a role of NCAN in BD, because its expression is localized to brain areas (cortex, hippocampus) in which abnormalities have been identified in BD. These abnormalities may be indicative of disturbances in key neuronal circuits.
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